

Table I-21
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2004^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			29-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 29 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 29 Years ^d
All Sites	4,000,969	4,077,054	4,404,865	10,133,875	10,325,806
Male	2,045,700	2,073,736	2,232,399	4,719,465	4,775,763
Female	1,955,269	2,003,318	2,172,466	5,414,410	5,550,043
Oral Cavity & Pharynx	84,371	96,606	99,624	217,906	238,970
Male	56,621	64,295	65,983	140,286	152,405
Female	27,750	32,311	33,641	77,620	86,565
Esophagus	17,196	20,284	20,296	24,565	28,664
Male	13,312	15,498	15,510	18,653	21,473
Female	3,884	4,786	4,786	5,912	7,191
Stomach	29,647	35,113	35,259	57,826	65,836
Male	17,872	21,205	21,244	33,280	37,946
Female	11,775	13,908	14,015	24,546	27,890
Colon & Rectum	413,172	475,209	483,080	1,026,682	1,141,407
Male	208,481	240,519	244,040	503,545	556,381
Female	204,691	234,690	239,040	523,137	585,026
Liver & Intrahep	14,336	16,338	16,338	19,061	21,427
Male	9,723	11,009	11,009	12,344	13,826
Female	4,613	5,329	5,329	6,717	7,601
Pancreas	21,231	25,021	25,021	27,987	32,353
Male	10,156	12,184	12,184	13,235	15,435
Female	11,075	12,837	12,837	14,752	16,918
Larynx	31,966	36,772	37,057	90,186	98,875
Male	25,659	29,412	29,650	72,417	79,020
Female	6,307	7,360	7,407	17,769	19,855
Lung & Bronchus	206,480	254,806	259,381	345,236	412,115
Male	101,519	126,137	128,221	167,413	199,420
Female	104,961	128,669	131,160	177,823	212,695
Melanoma of the Skin	214,760	238,166	246,012	642,642	686,025
Male	113,145	127,550	132,610	317,120	341,495
Female	101,615	110,616	113,402	325,522	344,530
Breast					
Female	813,699	871,649	910,855	2,299,047	2,438,866
Cervix					
Female	41,612	43,636	43,691	186,488	191,924
Corpus & Uterus					
Female	144,321	161,682	161,696	500,188	540,981
Ovary ^f					
Female	54,533	63,083	63,116	148,412	166,361

^a US 2004 cancer prevalence counts are based on 2004 cancer prevalence proportions from the SEER 9 registries and 1/1/2004 US population estimates based on the average of 2003 and 2004 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 29 years (1975-2003); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1999-2003). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1999; Melanoma in 2000.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 29-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2004.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 29-year limited duration prevalence. The 1999 breast cancer is counted for the breast 5-year and 29-year limited duration prevalence.

In method (e) the 1999 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2000 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table I-21 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2004^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			29-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 29 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 29 Years ^d
Prostate					
Male	942,369	1,015,465	1,015,501	2,020,336	2,155,814
Testis					
Male	38,541	39,085	39,519	158,516	160,522
Urinary Bladder					
Male	185,870	226,468	229,260	489,252	560,822
Female	139,001	169,421	171,644	362,809	414,423
Female	46,869	57,047	57,616	126,443	146,399
Kidney & Renal Pelvis					
Male	98,835	119,954	120,885	228,714	264,104
Female	59,318	72,826	73,444	135,506	157,273
Female	39,517	47,128	47,441	93,208	106,831
Brain & Nervous System					
Male	38,349	40,291	40,487	100,542	103,478
Female	20,364	21,337	21,448	53,857	55,282
Female	17,985	18,954	19,039	46,685	48,196
Thyroid					
Male	103,273	111,414	111,642	321,227	337,609
Female	23,545	26,152	26,179	72,214	76,826
Female	79,728	85,262	85,463	249,013	260,783
Hodgkin Lymphoma					
Male	33,763	35,330	35,354	135,338	138,313
Female	17,936	18,787	18,798	70,330	71,915
Female	15,827	16,543	16,556	65,008	66,398
Non-Hodgkin Lymphoma					
Male	165,166	188,724	189,721	368,283	405,953
Female	86,010	98,988	99,481	190,649	209,512
Female	79,156	89,736	90,240	177,634	196,441
Myeloma					
Male	36,315	41,836	41,906	53,382	60,424
Female	20,046	23,478	23,548	29,616	33,879
Female	16,269	18,358	18,358	23,766	26,545
Leukemia					
Male	86,548	97,217	97,309	202,266	218,659
Female	50,266	56,859	56,917	114,783	124,335
Female	36,282	40,358	40,392	87,483	94,324
Acute Lymphocytic Leuk					
Male	13,978	14,185	14,185	49,880	50,189
Female	7,914	7,981	7,981	27,421	27,513
Female	6,064	6,204	6,204	22,459	22,676
Childhood (0-19)					
Male	58,085	58,205	58,498	237,628	238,095
Female	30,670	30,716	30,847	122,159	122,351
Female	27,415	27,489	27,651	115,469	115,744
Kaposi Sarcoma					
Male	6,370	6,864	6,864	20,160	21,169
Female	5,838	6,252	6,252	18,784	19,642
Female	532	612	612	1,376	1,527
Mesothelioma					
Male	2,668	3,333	3,333	4,161	4,920
Female	1,880	2,386	2,386	2,501	3,078
Female	788	947	947	1,660	1,842

^a US 2004 cancer prevalence counts are based on 2004 cancer prevalence proportions from the SEER 9 registries and 1/1/2004 US population estimates based on the average of 2003 and 2004 population estimates from the US Bureau of the Census.

^{bcde} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 29 years (1975-2003); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1999-2003). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1999; Melanoma in 2000.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 29-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2004.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 29-year limited duration prevalence. The 1999 breast cancer is counted for the breast 5-year and 29-year limited duration prevalence.

In method (e) the 1999 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2000 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table I-22
US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, January 1, 2004^a
BY AGE AT PREVALENCE

Age at Prevalence	Age Specific								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
<u>Site/Sex</u>									
All Sites									
Males	4,848,429	16,120	38,774	67,794	144,693	318,859	645,699	1,116,039	2,500,451
Females	5,913,785	14,522	31,876	73,689	212,191	581,836	1,039,847	1,258,340	2,701,485
Oral Cavity & Pharynx									
Males	150,946	46	527	1,324	3,270	14,521	32,689	37,725	60,844
Females	84,910	85	511	1,519	3,268	8,168	14,433	18,310	38,616
Esophagus									
Males	18,763	0	0	32	255	973	3,750	5,978	7,775
Females	6,022	0	12	23	33	226	854	1,378	3,497
Stomach									
Males	34,708	0	17	119	607	2,209	4,775	8,337	18,643
Females	25,592	33	23	105	446	1,708	3,234	4,649	15,394
Colon & Rectum									
Males	521,676	0	46	822	4,958	20,770	62,456	115,774	316,850
Females	554,659	11	75	819	4,801	19,051	52,318	94,583	383,002
Liver & Intrahep									
Males	12,411	263	389	319	267	1,237	4,028	2,656	3,252
Females	7,018	389	369	267	359	624	1,127	1,435	2,448
Pancreas									
Males	13,423	0	47	46	250	1,182	2,659	3,674	5,567
Females	15,024	0	63	147	356	1,206	2,256	3,699	7,297
Larynx									
Males	76,247	0	0	45	244	2,757	10,911	21,016	41,274
Females	18,600	0	0	46	230	1,255	2,655	5,229	9,185
Lung & Bronchus									
Males	174,880	23	73	268	1,109	6,906	24,315	50,502	91,686
Females	183,248	0	33	329	1,478	8,138	24,765	50,219	98,287
Melanoma of the Skin									
Males	333,330	55	769	4,499	16,117	46,145	75,025	76,142	114,578
Females	356,691	68	870	9,662	30,498	66,872	82,644	64,932	101,145

^a US 2004 cancer prevalence counts are based on 2004 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2004 US population estimates based on the average of 2003 and 2004 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 29 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table I-22 - continued
US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, January 1, 2004^a
 BY AGE AT PREVALENCE

Age at Prevalence	Age Specific								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
<u>Site/Sex</u>									
Breast									
Males	12,270	0	12	0	91	532	1,950	3,278	6,407
Females	2,407,943	0	82	2,097	35,151	203,932	471,756	578,108	1,116,817
Cervix									
Females	250,726	0	23	2,300	19,359	45,393	54,883	49,076	79,691
Corpus & Uterus, NOS									
Females	568,407	0	33	550	4,497	22,806	71,239	117,700	351,581
Ovary ^d									
Females	172,765	57	990	3,128	7,443	21,361	35,354	39,174	65,259
Prostate									
Males	2,024,489	34	58	103	282	15,786	167,564	509,996	1,330,665
Urinary Bladder									
Males	377,523	39	109	680	2,499	12,816	40,436	84,367	236,576
Females	134,267	22	45	375	1,333	4,592	12,214	26,715	88,970
Kidney & Renal Pelvis									
Males	141,899	1,550	2,415	2,125	3,869	12,865	26,944	36,480	55,651
Females	98,367	1,636	2,499	2,462	3,637	9,204	15,277	21,466	42,186
Hodgkin Lymphoma									
Males	78,455	175	2,171	8,440	16,776	21,227	16,175	8,444	5,048
Females	72,752	78	1,567	8,936	17,183	20,266	13,657	6,072	4,995
Non-Hodgkin Lymphoma									
Males	197,416	704	3,407	6,025	11,723	24,843	38,664	44,245	67,805
Females	183,713	308	1,403	3,404	8,069	17,550	30,736	39,111	83,133
Myeloma									
Males	29,745	0	5	12	574	2,166	6,246	8,590	12,152
Females	23,967	0	0	33	248	1,346	4,192	6,198	11,950
Leukemia									
Males	117,771	5,715	10,976	9,236	8,274	10,308	15,154	21,104	37,003
Females	90,849	4,882	9,186	8,526	6,528	6,998	9,832	13,426	31,471
Acute Lymphocytic Leuk									
Males	29,334	4,841	9,521	7,192	4,745	1,602	640	513	279
Females	24,073	4,257	7,787	6,202	3,388	1,218	725	253	242

^a US 2004 cancer prevalence counts are based on 2004 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2004 US population estimates based on the average of 2003 and 2004 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 29 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.